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Immunotherapy has recently emerged as a promising form of treatment for several kinds of cancer. 
With the introduction of check-point blockade therapy remarkable results in a subset of patients 
have been observed. However, some patients do not benefit from this treatment, possibly due to the 
strength of the immunosuppressive tumor environment in these patients. To circumvent this, finding 
novel approaches for activation of the immune system is of high priority. 
Damage-associated molecular patterns (DAMPs) delivered to dendritic cells (DCs) in situ may aid 
in overcoming the suppressive tumor milieu and lead to DC maturation and activation of an 
efficient immune response. Recent evidence has shown that the cGAS/STING pathway, which can 
be stimulated by dsDNA, a potent DAMP, plays an important role in immune activation against 
cancer in murine tumor models. 
 
We have developed a novel DC-targeted adjuvant and tested it on human dendritic cells in vitro. 
We found that the targeted adjuvant was indeed able to activate human DCs, shown by upregulation 
of DC maturation markers and an increased ability to activate T cells. We have also shown that the 
observed maturation of human DCs is indeed dependent on the cGAS/STING pathway.  
